Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 26 Linguagem: Inglês
10.1200/jco.19.02627
ISSN1527-7755
AutoresVicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado,
Tópico(s)Ovarian cancer diagnosis and treatment
ResumoPatients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.
Referência(s)